BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37485666)

  • 21. Which Factors Are Associated with Local Control and Survival of Patients with Localized Pelvic Ewing's Sarcoma? A Retrospective Analysis of Data from the Euro-EWING99 Trial.
    Andreou D; Ranft A; Gosheger G; Timmermann B; Ladenstein R; Hartmann W; Bauer S; Baumhoer D; van den Berg H; Dijkstra PDS; Dürr HR; Gelderblom H; Hardes J; Hjorth L; Kreyer J; Kruseova J; Leithner A; Scobioala S; Streitbürger A; Tunn PU; Wardelmann E; Windhager R; Jürgens H; Dirksen U;
    Clin Orthop Relat Res; 2020 Feb; 478(2):290-302. PubMed ID: 31580267
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma.
    Park JY; Park SK; Kim DY; Kim JH; Kim YM; Kim YT; Nam JH
    Gynecol Oncol; 2011 Aug; 122(2):255-9. PubMed ID: 21565389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic factors and survival of patients with uterine sarcoma: a German unicenter analysis.
    Huss A; Klar M; Hasanov MF; Juhasz-Böss I; Bossart M
    Arch Gynecol Obstet; 2023 Mar; 307(3):927-935. PubMed ID: 35780401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989-2007.
    Park JY; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
    J Cancer Res Clin Oncol; 2008 Dec; 134(12):1277-87. PubMed ID: 18506484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of Clinical and Surgical Factors on Uterine Carcinosarcoma Survival.
    Gracia M; Yildirim Y; Macuks R; Mancari R; Achimas-Cadariu P; Polterauer S; Iacoponi S; Zapardiel I;
    Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of adjuvant chemotherapy and pelvic radiation on pattern of recurrence and outcome in stage I non-invasive uterine papillary serous carcinoma. A multi-institution study.
    Mahdi H; Elshaikh MA; DeBenardo R; Munkarah A; Isrow D; Singh S; Waggoner S; Ali-Fehmi R; Morris RT; Harding J; Moslemi-Kebria M
    Gynecol Oncol; 2015 May; 137(2):239-44. PubMed ID: 25641568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Uterine sarcoma in Tunisia: retrospective study about 14 cases].
    Bouzid N; Kanoun Belajouza S; Boussen H; Bouaouina N
    Gynecol Obstet Fertil; 2014 Dec; 42(12):838-43. PubMed ID: 25155830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of tumor fragmentation in patients with stage I uterine leiomyosarcoma on patterns of recurrence and oncologic outcome.
    Pedra Nobre S; Hensley ML; So M; Zhou QC; Iasonos A; Leitao MM; Ducie J; Chiang S; Mueller JJ; Abu-Rustum NR; Zivanovic O
    Gynecol Oncol; 2021 Jan; 160(1):99-105. PubMed ID: 33158511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retrospective analysis of adjuvant treatment for localized, operable uterine leiomyosarcoma.
    Chantharasamee J; Wong K; Potivongsajarn P; Qorbani A; Motamed N; Brackert S; Cohen J; Chmielowski B; Kalbasi A; Rao J; Nelson S; Singh A
    Cancer Med; 2022 Aug; 11(15):2906-2912. PubMed ID: 35307963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterizing the efficacy and trends of adjuvant therapy versus observation in women with early stage (uterine confined) leiomyosarcoma: a National Cancer Database study.
    Costales AB; Radeva M; Ricci S
    J Gynecol Oncol; 2020 May; 31(3):e21. PubMed ID: 32266798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome.
    Callister M; Ramondetta LM; Jhingran A; Burke TW; Eifel PJ
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):786-96. PubMed ID: 14967435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic factors and impact of adjuvant chemotherapy for uterine leiomyosarcoma.
    Wu TI; Chang TC; Hsueh S; Hsu KH; Chou HH; Huang HJ; Lai CH
    Gynecol Oncol; 2006 Jan; 100(1):166-72. PubMed ID: 16182349
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic factors and survival in patients treated surgically for primary and recurrent uterine leiomyosarcoma: a single center experience.
    Bacalbasa N; Balescu I; Dima S; Brasoveanu V; Popescu I
    Anticancer Res; 2015 Apr; 35(4):2229-34. PubMed ID: 25862883
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Impact of Adjuvant Therapy on Survival and Recurrence Patterns in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study.
    Guttmann DM; Li H; Sevak P; Grover S; Jacobson G; Feldman A; Rubin S; Chu C; Bhatia S; Elshaikh MA; Lin LL
    Int J Gynecol Cancer; 2016 Jan; 26(1):141-8. PubMed ID: 26509850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognosis and treatment of uterine leiomyosarcoma: A National Cancer Database study.
    Seagle BL; Sobecki-Rausch J; Strohl AE; Shilpi A; Grace A; Shahabi S
    Gynecol Oncol; 2017 Apr; 145(1):61-70. PubMed ID: 28317559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical status and prognostic factors in Japanese patients with uterine leiomyosarcoma.
    Takehara K; Yamashita N; Watanabe R; Teramoto N; Tsuda H; Motohashi T; Harano K; Nakanishi T; Tokunaga H; Susumu N; Ueda Y; Yokoyama Y; Saito T
    Gynecol Oncol; 2020 Apr; 157(1):115-120. PubMed ID: 31983515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990-1999) at the Massachusetts General Hospital.
    Dinh TA; Oliva EA; Fuller AF; Lee H; Goodman A
    Gynecol Oncol; 2004 Feb; 92(2):648-52. PubMed ID: 14766261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metachronous Peritoneal Metastases After Adjuvant Chemotherapy are Associated with Poor Outcome After Cytoreduction and HIPEC.
    Sluiter NR; Rovers KP; Salhi Y; Vlek SL; Coupé VMH; Verheul HMW; Kazemier G; de Hingh IHJT; Tuynman JB
    Ann Surg Oncol; 2018 Aug; 25(8):2347-2356. PubMed ID: 29855834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic factors and treatment outcomes in 93 patients with uterine sarcoma from 4 centers in Turkey.
    Durnali A; Tokluoğlu S; Özdemir N; Inanç M; Alkiş N; Zengin N; Sönmez ÖU; Küçüköner M;
    Asian Pac J Cancer Prev; 2012; 13(5):1935-41. PubMed ID: 22901150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study.
    Hensley ML; Ishill N; Soslow R; Larkin J; Abu-Rustum N; Sabbatini P; Konner J; Tew W; Spriggs D; Aghajanian CA
    Gynecol Oncol; 2009 Mar; 112(3):563-7. PubMed ID: 19135708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.